Compass Therapeutics Ownership | Who Owns Compass Therapeutics?

Compass Therapeutics Ownership Summary

Compass Therapeutics is owned by 10.56% institutional investors, 12.46% insiders, and 76.99% retail investors. Tang capital management is the largest institutional shareholder, holding 10.65% of CMPX shares. Biotech Growth Ord is the top mutual fund, with 2.58% of its assets in Compass Therapeutics shares.

CMPX Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Compass Therapeutics	10.56%	12.46%	76.99%
Sector	Healthcare Stocks	35.71%	11.88%	52.42%
Industry	Biotech Stocks	35.98%	11.86%	52.17%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Tang capital management	16.79M	10.65%	$88.82M
Orbimed advisors	15.22M	9.65%	$80.51M
Suvretta capital management	14.31M	9.07%	$75.69M
Vivo capital	9.55M	6.05%	$50.50M
Blackrock funding, inc. /de	9.51M	6.03%	$50.29M
Vanguard group	8.05M	5.82%	$43.22M
Adage capital partners gp	8.49M	5.38%	$44.89M
Enavate sciences gp	7.79M	4.94%	$41.20M
Bvf inc/il	7.76M	4.92%	$41.08M
Blackrock	6.61M	4.84%	$6.61M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Enavate sciences gp	7.79M	11.72%	$41.20M
Tang capital management	16.79M	4.51%	$88.82M
Birchview capital, lp	1.47M	4.41%	$7.75M
Vivo capital	9.55M	4.21%	$50.50M
Blue owl capital lp	2.94M	4.18%	$15.56M
Acuta capital partners	849.08K	3.17%	$4.49M
Bioimpact capital	5.08M	2.91%	$17.77M
Suvretta capital management	14.31M	1.93%	$75.69M
Great point partners	1.35M	1.64%	$7.14M
Orbimed advisors	15.22M	1.60%	$80.51M

Top Buyers

Holder	Shares	% Assets	Change
Adage capital partners gp	8.49M	0.07%	4.05M
Ubs group	2.39M	0.00%	2.22M
Qube research	2.55M	0.01%	2.11M
Logos global management lp	3.15M	0.83%	2.00M
State street	6.69M	0.00%	1.80M

Top Sellers

Holder	Shares	% Assets	Change
Blackstone	1.86M	0.04%	-4.27M
Opaleye management	-	-	-3.17M
Millennium management	846.22K	0.00%	-2.26M
Cormorant asset management, lp	-	-	-2.03M
Sofinnova investments	2.06M	0.41%	-1.31M

New Positions

Holder	Shares	% Assets	Change	Value
Great point partners	1.35M	1.64%	1.35M	$7.14M
Fisher asset management	1.35M	0.00%	1.35M	$7.13M
Vanguard fiduciary trust	998.14K	0.00%	998.14K	$5.28M
Arrowmark colorado	514.79K	0.07%	514.79K	$2.72M
Trexquant investment lp	421.83K	0.02%	421.83K	$2.23M

Sold Out

Holder	Change
Clearstead advisors	-4.00
Nelson, van denburg & campbell wealth management group	-16.00
Srs capital advisors	-18.00
True wealth design	-20.00
Capital performance advisors llp	-172.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2026	66	-60.95%	16,644,827	-89.86%	10	0.07%	37	-68.38%	17	-48.48%
Dec 31, 2025	107	-15.75%	57,926,851	-61.65%	41	0.35%	77	2.67%	16	-48.39%
Sep 30, 2025	122	15.09%	151,030,990	39.52%	109	1.78%	70	62.79%	31	-27.91%
Jun 30, 2025	105	-18.60%	108,229,435	-0.20%	78	1.26%	42	-37.31%	43	48.28%
Mar 31, 2025	10	-89.01%	39,938,686	-60.60%	29	0.53%	5	-91.07%	2	-88.24%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Biotech Growth Ord	3.57M	2.58%	-
Vanguard Total Stock Mkt Idx Inv	4.19M	2.33%	-
State Street® SPDR® S&P® Biotech ETF	4.00M	2.22%	-40.58K
iShares Russell 2000 ETF	3.04M	1.69%	25.61K
Vanguard US Total Market Shares ETF	2.19M	1.58%	-
Vanguard Institutional Extnd Mkt Idx Tr	1.72M	0.96%	8.82K
Fidelity Small Cap Index	1.28M	0.71%	11.94K
Simplify Propel Opportunities ETF	720.00K	0.52%	600.00K
Russell 2000 Equity Index Fund B	822.95K	0.46%	219.10K
Fidelity Extended Market Index	816.28K	0.45%	10.70K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Apr 29, 2026	Lerner Neil	Chief Accounting Officer	Buy	$28.35K
Apr 29, 2026	Anderman Jonathan	General Counsel	Buy	$47.25K
May 27, 2025	Schuetz Thomas J.	CHIEF EXECUTIVE OFFICER	Buy	$21.10K
Apr 09, 2025	GORDON CARL L		Sell	$5.68M
Apr 09, 2025	ORBIMED ADVISORS LLC		Sell	$5.68M

Insider Transactions Trends

Date	Buy	Sell
2026 Q2	2	-
2026 Q1	-	-
2025 Q4	-	-
2025 Q2	3	2
2025 Q1	-	-

CMPX Ownership FAQ

Who Owns Compass Therapeutics?

Compass Therapeutics shareholders are primarily institutional investors at 10.56%, followed by 12.46% insiders and 76.98% retail investors. The average institutional ownership in Compass Therapeutics's industry, Biotech Stocks , is 35.98%, which Compass Therapeutics falls below.

Who owns the most shares of Compass Therapeutics?

Compass Therapeutics’s largest shareholders are Tang capital management (16.79M shares, 10.65%), Orbimed advisors (15.22M shares, 9.65%), and Suvretta capital management (14.31M shares, 9.07%). Together, they hold 29.37% of Compass Therapeutics’s total shares outstanding.

Does Blackrock own Compass Therapeutics?

Yes, BlackRock owns 4.84% of Compass Therapeutics, totaling 6.61M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 6.61M$. In the last quarter, BlackRock increased its holdings by 581.17K shares, a 9.63% change.

Who is Compass Therapeutics’s biggest shareholder by percentage of total assets invested?

Enavate sciences gp is Compass Therapeutics’s biggest shareholder by percentage of total assets invested, with 11.72% of its assets in 7.79M Compass Therapeutics shares, valued at 41.2M$.

Who is the top mutual fund holder of Compass Therapeutics shares?

Biotech Growth Ord is the top mutual fund holder of Compass Therapeutics shares, with 2.58% of its total shares outstanding invested in 3.57M Compass Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools